Capitolis Liquid Global Markets LLC Sells 29,000 Shares of Intuitive Surgical, Inc. $ISRG

Capitolis Liquid Global Markets LLC cut its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 40.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 43,000 shares of the medical equipment provider’s stock after selling 29,000 shares during the period. Capitolis Liquid Global Markets LLC’s holdings in Intuitive Surgical were worth $19,231,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Rossmore Private Capital raised its stake in Intuitive Surgical by 2.0% in the 3rd quarter. Rossmore Private Capital now owns 998 shares of the medical equipment provider’s stock worth $446,000 after purchasing an additional 20 shares in the last quarter. Activest Wealth Management grew its position in shares of Intuitive Surgical by 21.7% during the 3rd quarter. Activest Wealth Management now owns 112 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 20 shares in the last quarter. Vertex Planning Partners LLC increased its holdings in shares of Intuitive Surgical by 2.3% during the second quarter. Vertex Planning Partners LLC now owns 917 shares of the medical equipment provider’s stock worth $498,000 after purchasing an additional 21 shares during the period. Accredited Investors Inc. increased its holdings in shares of Intuitive Surgical by 2.0% during the third quarter. Accredited Investors Inc. now owns 1,060 shares of the medical equipment provider’s stock worth $474,000 after purchasing an additional 21 shares during the period. Finally, SPC Financial Inc. raised its position in shares of Intuitive Surgical by 1.3% in the third quarter. SPC Financial Inc. now owns 1,614 shares of the medical equipment provider’s stock valued at $722,000 after buying an additional 21 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Insider Activity at Intuitive Surgical

In related news, VP Fredrik Widman sold 133 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $494.96, for a total transaction of $65,829.68. Following the sale, the vice president directly owned 660 shares of the company’s stock, valued at approximately $326,673.60. The trade was a 16.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Mark Brosius sold 645 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $485.01, for a total transaction of $312,831.45. Following the transaction, the senior vice president owned 1,613 shares of the company’s stock, valued at approximately $782,321.13. This represents a 28.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 33,407 shares of company stock valued at $17,534,067. Company insiders own 0.70% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ISRG shares. UBS Group set a $570.00 price target on Intuitive Surgical and gave the company a “neutral” rating in a research note on Tuesday, February 24th. Robert W. Baird dropped their price objective on Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Truist Financial upped their target price on Intuitive Surgical from $620.00 to $650.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. BTIG Research restated a “buy” rating and issued a $616.00 price target on shares of Intuitive Surgical in a research report on Friday, January 23rd. Finally, HSBC boosted their price target on Intuitive Surgical from $644.00 to $653.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $615.86.

Intuitive Surgical Stock Down 1.5%

Shares of ISRG stock opened at $472.16 on Friday. The business has a fifty day simple moving average of $513.26 and a 200 day simple moving average of $512.67. The company has a market cap of $167.68 billion, a P/E ratio of 59.84, a P/E/G ratio of 3.64 and a beta of 1.66. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.26. The firm had revenue of $2.87 billion for the quarter, compared to analysts’ expectations of $2.72 billion. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The business’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.21 earnings per share. As a group, equities research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: FDA clearance expands da Vinci 5 into cardiac surgery, opening a much larger long-term TAM (management cites a jump from ~17k to ~160k addressable procedures in cleared markets) — a multi-year growth driver for procedure volume and consumables. Read More.
• Positive Sentiment: Completed acquisition of Southern Europe distributor businesses (Italy, Spain, Portugal) shifts da Vinci and Ion sales to direct operations — should improve control of regional sales/service and capture margin/recurring revenue over time. Read More.
• Positive Sentiment: Sell-side momentum: Citigroup upgraded ISRG to Buy and several analysts maintain bullish price targets, supporting upside thesis and sentiment. Read More.
• Positive Sentiment: Recent Q4 results beat consensus (strong revenue and EPS growth), reinforcing recurring-consumables revenue and the upgrade cycle for da Vinci systems. Read More.
• Neutral Sentiment: Analyst consensus shows meaningful upside (Zacks highlights ~29.7% average target upside), but that depends on execution and multiple expansion remaining intact. Read More.
• Neutral Sentiment: Long-form bullish pieces reiterate a multi-year growth story from da Vinci 5, Ion and software/services but don’t change near-term valuation concerns. Read More.
• Negative Sentiment: Cybersecurity incident (phishing-linked breach affecting internal systems) is the immediate catalyst for the share decline — investors will watch for customer impact, data exposure, and remediation costs. Read More.
• Negative Sentiment: Insider selling (recent EVP share sales) and management guidance calling for a deceleration in worldwide da Vinci procedure growth in 2026 could pressure near-term sentiment and valuation. Read More. • Read More.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.